XML 40 R19.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Long-Term Debt | 12 Months Ended
--- | ---
Dec. 31, 2023
Long-Term Debt [Abstract] |
LONG-TERM DEBT | NOTE 12 – LONG-TERM DEBT Long-term debt consisted of the following at December 31, 2023 and 2022:
|  | 2023 |  |  | 2022 |
Term loan, due in 2027 |  | $ | 38,290,000 |  |  | $ | — |
Less: current portion of long-term debt |  |  | (2,000,000 | ) |  |  | — |
Less: unamortized issuance costs |  |  | (2,059,263 | ) |  |  | — |
Long-term debt, net |  | $ | 34,230,737 |  |  | $ | — |
On October 11, 2023, the Company entered into a Financing Agreement (the “Financing”) which provided for a term loan (the “Term Loan”) of $40 million, the net proceeds of which were used to partially finance the Medicx Health transaction described in Note 3 “Acquisitions”. In connection with the Financing the Company incurred issuance costs of approximately $2.3 million, which were capitalized and are being amortized to interest expense over the life of the Term Loan. Amortization of debt issuance costs for the year ended December 31, 2023, was $210,737. The Company’s obligations under the Financing are secured by all of the Company’s and its subsidiaries’ assets (including a pledge of all of the capital stock and equity interests of its subsidiaries). The Term Loan is repayable in quarterly installments, beginning December 31, 2023, equivalent to 1.25% or $500,000, of the original principal amount, with the outstanding unpaid principal and all accrued but unpaid interest due and payable on the earlier of (i) the fourth anniversary of the closing date of the Term Loan or (ii) the date on which the Term Loan is declared due and payable pursuant to the terms of the Financing. The Company may prepay, subject to an Applicable Premium, 3% if the prepayment is made on a date that is up to and including the first anniversary of closing, 2%, if the prepayment is made up to and including the second anniversary, 1% if the prepayment is made up to and including the third anniversary and zero thereafter, all or a portion of the Term Loan and, under certain circumstances, including certain asset disposals and the raising of indebtedness not permitted under the Financing is required to make mandatory prepayments of the principal balance. If the prepayment occurs within 12 months of the date of the loan, the Company is also required to pay lost interest from the prepayment date to one year from the loan funding date. In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00. Excess Cash Flow is defined in the Financing as Consolidated EBITDA for the previous fiscal year less scheduled principal and interest payments, capital expenditure, cash taxes and any cash expenses/gains added back to net income in the calculation of Consolidated EBITDA, adjusted for any increase/decrease in working capital during the fiscal year. During the year ended December 31, 2023, the Company made total principal repayments of $1.7 million, including a mandatory prepayment of $1.2 million as a result of an asset sale completed during the year. At the Company’s option the Term Loan, or any portion thereof bears interest at either:
| a. | The greater of (a) 4.00% per annum, (b) the Federal Funds Rate plus 0.50% per annum, (c) the one month Secured Funds Overnight Rate (“SOFR”), plus an adjustment of 26.161 basis point and 1.00% per annum, and (d) the rate last quoted by The Wall Street Journal as the “Prime Rate”, plus an Applicable Margin of 7.5%; or
| b. | Three-month SOFR plus an adjustment of 26.161 basis points and an Applicable Margin of 8.5%
As of December 31, 2023, the Loan bears interest at 14.1% per annum, with the effective interest rate for the year ended December 31, 2023, including the amortization of debt issuance costs and Applicable Premium and interest penalties of $181,895 associated with the prepayment during the year ended December 31, 2023, was 19.6%. The Financing requires the Company to maintain the following financial covenants:
| a. | A maximum leverage ratio, as defined in the Financing as follows:
Fiscal Quarter End |  | Leverage ratio |
March 31, 2024 |  | 4.50 to 1.00 |
June 30, 2024 |  | 4.00 to 1.00 |
September 30, 2024 |  | 3.50 to 1.00 |
December 31, 2024 |  | 3.00 to 1.00 |
March 31, 2025 |  | 2.50 to 1.00 |
June 30, 2025 |  | 2.25 to 1.00 |
September 30, 2025, and thereafter |  | 2.00 to 1.00 |
| b. | Liquidity, as defined in the Financing, of at least $5.0 million.
The Company was in compliance with its financial covenants as of December 31, 2023, and received a waiver from its lender to extend the date for providing the Company's audited financial statements from March 31, 2024, to April 15, 2024. The Financing contains customary events of default, which include, (subject to, in certain circumstances to grace and cure periods), non-payment of principal and interest, non-compliance with certain covenants, commencement of bankruptcy proceedings and a change in control. Payments due on the Loan in each of the next four years subsequent to December 31, 2023, are as follows:
For the year ending December 31, |  |  |
2024 |  | $ | 2,000,000 |
2025 |  |  | 2,000,000 |
2026 |  |  | 2,000,000 |
2027 |  |  | 32,290,000 |
|  | $ | 38,290,000 |

X
- References No definition available. + Details
Name: | us-gaap_LongTermDebtOtherDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for long-term debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent + Details
Name: | us-gaap_LongTermDebtTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration